AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by stock analysts at Jefferies Financial Group in a report issued on Friday, Borsen Zeitung reports. They currently have a GBX 7,475 ($98.33) price objective on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 2.40% from the company’s previous close.
A number of other analysts also recently weighed in on AZN. HSBC reissued a “reduce” rating and set a GBX 6,235 ($82.02) price target on shares of AstraZeneca in a research report on Wednesday, November 27th. Bryan, Garnier & Co reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, December 19th. Barclays raised their price target on shares of AstraZeneca from GBX 8,300 ($109.18) to GBX 8,500 ($111.81) and gave the stock an “overweight” rating in a research report on Thursday, January 16th. Citigroup reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, January 28th. Finally, Liberum Capital raised their price target on shares of AstraZeneca from GBX 8,300 ($109.18) to GBX 8,810 ($115.89) and gave the stock a “buy” rating in a research report on Wednesday, January 22nd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. AstraZeneca currently has a consensus rating of “Buy” and a consensus target price of GBX 7,912.14 ($104.08).
AZN stock opened at GBX 7,300 ($96.03) on Friday. AstraZeneca has a twelve month low of GBX 109.51 ($1.44) and a twelve month high of GBX 8,227.88 ($108.23). The company has a current ratio of 0.92, a quick ratio of 0.70 and a debt-to-equity ratio of 148.59. The company has a market capitalization of $95.79 billion and a P/E ratio of 45.80. The firm has a 50 day simple moving average of GBX 7,666.44 and a 200-day simple moving average of GBX 7,335.03.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Why Invest in Dividend Achievers?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.